Healthcare Equipment and Supplies
Company Overview of ElectroCore, LLC
ElectroCore, LLC operates as a healthcare company that focuses on neuromodulation therapies for the treatment of diseases and disorders. The company develops non-invasive and non-pharmacologic therapies that treat or prevent symptoms of serious headache conditions, bronchoconstriction, and canine epilepsy by sending a mild electrical signal through the skin to stimulate the vagus nerve. It focuses on neuromodulation therapies for the treatment of diseases and disorders. It offers AlphaCore therapy, a vagus nerve stimulator for the treatment or prevention of symptoms of reactive airway disease, including asthma, COPD, and exercise-induced asthma/bronchospasm; and GammaCore therapy, a vagus ne...
51 Gibraltar Drive
Morris Plains, NJ 07950
Founded in 2005
Key Executives for ElectroCore, LLC
Co-Founder and Chief Science Officer
Vice President of Finance
Compensation as of Fiscal Year 2014.
ElectroCore, LLC Key Developments
ElectroCore, LLC Presents at EuroMedtech 2014, May-07-2014 05:00 PM
Mar 20 14
ElectroCore, LLC Presents at EuroMedtech 2014, May-07-2014 05:00 PM. Venue: Marriott Linz Hotel, Europaplatz 2, A-4020, Linz, Austria. Speakers: J. P. Errico, Co-Founder, Chief Executive Officer and Director.
electroCore's Clinical Trial Program into Non Invasive Vagus Nerve Stimulation Therapy Gathers Momentum
Oct 31 13
electroCore has announced that its European randomized controlled trial, GC - 002, for the prevention and acute treatment of chronic cluster headache has been found by the external statistical team to require no changes based on the planned interim sizing analysis. This study, which is a multicentre trial with sites in Germany -5, UK -3, Belgium -1, Italy -1, has as its primary outcome the reduction in the number of cluster headache attacks per week. The trial is a randomized controlled study involving parallel groups. One arm receiving the standard of care while the other arm is receiving the standard of care plus treatment with gammaCore - electroCore's non invasive vagus nerve stimulation (nVNS) therapy. The trial, which is due to finish at the end of the second quarter next year, has already enrolled 58 patients with a target total of 90 patients. electroCore's extensive clinical trials program is continuing to explore the potential of its revolutionary non invasive vagus nerve stimulation therapy across a number of conditions. Surgically invasive vagus nerve stimulation therapy has proven to be very effective in epilepsy and depression but because of its very high cost is not used except as a last resort. Its high cost has also deterred research into the many conditions where it is reported to have been effective.
ElectroCore Signs $14 Million Development Agreement with waveCore
Oct 9 13
ElectroCore has expanded its portfolio of vagus nerve stimulation (VNS) delivery technologies by signing a development agreement with waveCore. waveCore has agreed to pay electroCore $14 million based on development milestones. waveCore has the rights to a technology capable of transmitting both the signal and power from a transmitter outside the body to a miniature implanted vagus nerve electrode. waveCore, which initially secured the rights to the technology in May 2013, is a company owned by the founding shareholders of electroCore. The first milestone payment of $2 million will be paid immediately to electroCore, to achieve the first in man pilot study. Following this milestone, a second $4 million payment will be made to achieve FDA approval of pivotal study, and the final $8 million will become due when a PMA approval is granted.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|